IN2012MN02923A - - Google Patents

Info

Publication number
IN2012MN02923A
IN2012MN02923A IN2923MUN2012A IN2012MN02923A IN 2012MN02923 A IN2012MN02923 A IN 2012MN02923A IN 2923MUN2012 A IN2923MUN2012 A IN 2923MUN2012A IN 2012MN02923 A IN2012MN02923 A IN 2012MN02923A
Authority
IN
India
Prior art keywords
dosage forms
present
gaba
gastroretentive dosage
swelling
Prior art date
Application number
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Res Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Res Private Ltd filed Critical Rubicon Res Private Ltd
Priority to IN2923MUN2012 priority Critical patent/IN2012MN02923A/en
Publication of IN2012MN02923A publication Critical patent/IN2012MN02923A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Abstract

The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid ('GABA') analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant.
IN2923MUN2012 2010-06-01 2011-06-01 IN2012MN02923A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2923MUN2012 IN2012MN02923A (en) 2010-06-01 2011-06-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1676MU2010 2010-06-01
PCT/IB2011/001200 WO2011151708A1 (en) 2010-06-01 2011-06-01 Gastroretentive dosage forms of gaba analogs
IN2923MUN2012 IN2012MN02923A (en) 2010-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
IN2012MN02923A true IN2012MN02923A (en) 2015-06-05

Family

ID=54199435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2923MUN2012 IN2012MN02923A (en) 2010-06-01 2011-06-01

Country Status (4)

Country Link
US (1) US20130078290A1 (en)
EP (1) EP2575798B1 (en)
IN (1) IN2012MN02923A (en)
WO (1) WO2011151708A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809303A1 (en) 2012-01-30 2014-12-10 Ranbaxy Laboratories Limited Pregabalin gr tablets
WO2013114283A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Gastroretentive tablets
EP2698144A1 (en) * 2012-08-12 2014-02-19 Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi Prolonged release gabapentin tablet formulation whose ability to stay in the stomach is improved
WO2014060952A1 (en) 2012-10-16 2014-04-24 Ranbaxy Laboratories Limited Osmotic floating tablets
FR3014692B1 (en) * 2013-12-18 2016-01-29 Ethypharm Sa ORAL PHARMACEUTICAL COMPOSITIONS WITH GASTRIC RETENTION.
EP3099288A1 (en) * 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (en) * 2014-04-07 2021-02-26 영진약품 주식회사 Pharmaceutical composition of pregabalin with improved stability and method for preparing thereof
WO2015174684A1 (en) * 2014-05-14 2015-11-19 동아에스티 주식회사 Release-controlled gastroretentive extended-release preparation
US10813898B2 (en) * 2016-03-10 2020-10-27 Orphelia Pharma Solid dosage forms of vigabatrin
WO2018001582A1 (en) * 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
KR102039345B1 (en) 2017-02-01 2019-11-01 지엘팜텍주식회사 A high swellable sustained-release triple-layer tablet containing pregabalin
KR102039344B1 (en) * 2017-02-01 2019-11-01 지엘팜텍주식회사 An orally administered sustained-release triple-layer tablet containing pregabalin
KR102083241B1 (en) * 2018-02-14 2020-03-02 환인제약 주식회사 Pharmaceutical sustained-release composition containing lacosamide
US11938222B2 (en) * 2018-06-13 2024-03-26 Beijing Tide Pharmaceutical Co., Ltd. Pregabalin sustained release composition and method for preparing the same
US11147767B2 (en) * 2019-02-25 2021-10-19 Rubicon Research Private Limited Gastroretentive formulations
FI3760190T3 (en) * 2019-07-03 2023-08-09 Alvogen Inc Controlled-release tablets of pregabalin, method of making, and method of use thereof
CN112741827B (en) * 2019-10-31 2022-07-08 武汉武药科技有限公司 Vigabatrin solid preparation and preparation method thereof
KR20240039030A (en) * 2021-07-30 2024-03-26 에벡시아 테라퓨틱스 아이엔씨. 5-Hydroxytryptophan Gastroretentive Dosage Form
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
CN114796142A (en) * 2022-04-08 2022-07-29 黄山学院 Naproxen gastric floating tablet and preparation method thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (en) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2255652C (en) 1996-07-24 2004-07-13 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
PT1003476E (en) * 1997-08-11 2005-05-31 Alza Corp ACTIVE AGGREGATE AGGREGATE DOSAGE FORM ADAPTED FOR GASTRIC RETENTION
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
WO2003011255A1 (en) 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CN1668284A (en) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 Sustained release oral dosage forms of gabapentin
NL2000281C2 (en) * 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
JP2009522294A (en) * 2005-12-29 2009-06-11 デポメッド， インコーポレイテッド Gastric retention type gabapentin dosage form and method of use thereof
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
EP2378883B1 (en) * 2008-12-04 2015-12-23 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2010143052A1 (en) 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
KR101317592B1 (en) 2009-10-28 2013-10-15 씨제이제일제당 (주) Gastric-retentive sustained release fomulation containing pregabalin and pva-peg graft copolymer

Also Published As

Publication number Publication date
EP2575798B1 (en) 2017-08-09
WO2011151708A1 (en) 2011-12-08
EP2575798A1 (en) 2013-04-10
US20130078290A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
IN2012MN02923A (en)
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
PH12015501385A1 (en) Autotaxin inhibitors
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
UA109661C2 (en) Pharmaceutical compositions comprising co-crystals of tramadol and celecoxib
MX2012012225A (en) Nitric oxide releasing prodrugs of therapeutic agents.
MX2010002210A (en) Catecholamine derivatives and prodrugs thereof.
MX2013001677A (en) Stable formulations of linaclotide.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX2019012939A (en) Linaclotide-containing formulations for oral administration.
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX340147B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
MX344846B (en) Combination of active loaded granules with additional actives.
PH12015500823A1 (en) Modified release formulations for oprozomib
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
MX2012008413A (en) Novel retigabine composition.
UY33723A (en) ? COMPOUNDS AND ITS USE FOR TREATMENT OF DISEASES RELATED TO Aß ?.
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
MX2012015102A (en) Therapeutic agents 976.
UY32894A (en) DERIVATIVES OF 5-PHENYL-PIRAZOLOPIRIDINE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
UA93515C2 (en) Medicinal agent based on rutin
TN2011000018A1 (en) Pharmaceutical formulations containing dopamine receptor ligands